Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News | Request a free trial
May 5, 2008
BITE antibodies for solid tumors: Still more bark than bite!!!
Analysis of: Micromet Enrolls First Patient in Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors | www.pipelinereview.com
Author: GLG Expert Contributor
Micromet's Bite antibodies strategy garners the patient's T-cells to attack tumor cells. This technology showed proof of principle i hematological malignancies , and now a Phase I clinical trial has commenced for solid tumors. The rationale is intriguing, but immunotherapy has been elusive in solid...
May 1, 2008
Genomics!!! I told you so......
Analysis of: New Study Ties Genes To Leukemia Treatment | online.wsj.com
Author: GLG Expert Contributor
Gene mutation analysis can help refine therapy in acute leukemia and impact on results!!
April 30, 2008
Rituxan ( Vitamin R ): Let's not panic!!
Analysis of: Wider Aim for Rituxan Fails | online.wsj.com
Author: GLG Expert Contributor
Rituxan failed to improve various parameters and targets in a rather comprehensive study of patients with Lupus.
April 28, 2008
More potential developments in chronic lymphatic leukemia (CLL) therapy!
Analysis of: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
ZymoGenetic appears to have a biologic that will expedite lymphocytes apoptosis (destruction) when combined with Fludara and Rituxan- 2 standard agents in this rather common & occasional refractory condition.
April 28, 2008
A Non Epo Product for Anemia of Chemotherapy? Will this dog hunt?
Analysis of: Oral PBI-1402 Demonstrates Significant Activity in Chemeotherapy-Induced Anemia Phase II Clinical Trial | www.pipelinereview.com
Author: GLG Expert Contributor
This non erythropoietin (Epo) product will raise hemoglobin levels and decrease the need for transfusions.
April 24, 2008
Advance in Small Cell Lung Cancer (SCLC)?
Analysis of: Poniard reports positive results for lung cancer drug | www.cnbc.com
Author: GLG Expert Contributor
Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218
April 22, 2008
Thalidomide (Celgene) use to be liberalized in Europe
Analysis of: Thalidomide Gets Boost in Europe | online.wsj.com
Author: GLG Expert Contributor
Thalidomide literally started the improved outlook in MM along with, and followed by Velcade, Revlimid and Stem Cell transplants. To now have increased access in Europe should open up that market eventhough the other agents are in widespread use (I think)
April 22, 2008
Wellpoint restricting epo products. Am I surprised?? No!!
Analysis of: WellPoint likely to follow FDA on anemia drugs | www.reuters.com
Author: GLG Expert Contributor
A major insurer (Wellpoint) is using the guidelines of the FDA to restrict erythropoietin (Epo) use.
Donald FlemingApril 21, 2008
Why Xeloda can't eliminate 5FU
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight
April 21, 2008
Roche's Xeloda to gain more use in frontline treatment of m-CRC
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Xeloda, an oral agent, was non-inferior to infusional 5-FU, when combined ith oxaliplatin in a randomized trial in patients with metastatic colrectal cancer (m-CRC) In fact, Xeloda containing regimen was assocaited with less myelosuppression, but more rashes and diaarhea. This is good news for...

Previous Page : 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next151 to 160 of 889

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-04T21:45:18.380